DADI Stock Overview
Dar Al Dawa Development and Investment Co. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Dar Al Dawa Development and Investment Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.أ1.25 |
| 52 Week High | د.أ1.42 |
| 52 Week Low | د.أ1.21 |
| Beta | 0.20 |
| 11 Month Change | 1.63% |
| 3 Month Change | -2.34% |
| 1 Year Change | 0.81% |
| 33 Year Change | 3.31% |
| 5 Year Change | 9.65% |
| Change since IPO | -69.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| DADI | JO Pharmaceuticals | JO Market | |
|---|---|---|---|
| 7D | -3.1% | -1.8% | 0.6% |
| 1Y | 0.8% | 8.0% | 3.2% |
Return vs Industry: DADI underperformed the JO Pharmaceuticals industry which returned 8% over the past year.
Return vs Market: DADI underperformed the JO Market which returned 3.2% over the past year.
Price Volatility
| DADI volatility | |
|---|---|
| DADI Average Weekly Movement | 1.9% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JO Market | 5.9% |
| 10% least volatile stocks in JO Market | 1.3% |
Stable Share Price: DADI has not had significant price volatility in the past 3 months compared to the JO market.
Volatility Over Time: DADI's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1975 | 1,067 | Khaled Harb | www.dadgroup.com |
Dar Al Dawa Development and Investment Co. Ltd., an integrated pharmaceutical company, develops, produces, markets, and commercializes medicines and wellness consumer products. The company offers products in the therapeutic areas of anti-infective, cardiovascular and diabetes, nervous system, gastrointestinal, dermatology, eye-ear preparations, genitourinary system and sex hormones, analgesic, respiratory system, and vitamins and natural products. It serves patients in approximately 40 countries throughout the Middle East, North Africa, and Europe.
Dar Al Dawa Development and Investment Co. Ltd. Fundamentals Summary
| DADI fundamental statistics | |
|---|---|
| Market cap | د.أ43.75m |
| Earnings (TTM) | د.أ3.35m |
| Revenue (TTM) | د.أ77.95m |
13.1x
P/E Ratio0.6x
P/S RatioIs DADI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DADI income statement (TTM) | |
|---|---|
| Revenue | د.أ77.95m |
| Cost of Revenue | د.أ47.13m |
| Gross Profit | د.أ30.83m |
| Other Expenses | د.أ27.48m |
| Earnings | د.أ3.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.096 |
| Gross Margin | 39.54% |
| Net Profit Margin | 4.30% |
| Debt/Equity Ratio | 104.2% |
How did DADI perform over the long term?
See historical performance and comparison